Pomolic acid, triterpenoid isolated from Licania pittieri, as competitive antagonist of ADP-induced aggregation of human platelets

Alvarado-Castillo, Claudia; Estrada, Omar; Carvajal, Edilmo

doi:10.1016/j.phymed.2011.12.011

Cited by 14 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results also provide evidence to suggest that purinergic receptor blockers isolated from the plants L . pittieri may be beneficial for their use as antiplatelet agents in humans [31]. However, further investigations are warranted to provide more data in support of this evidence.…”

Section: +mentioning

confidence: 86%

“…There was also evidence in this study showing that PA (25-100 nM) acts as a competitive antagonist of ADP-induced (10 −6 -10 −3 M) platelet aggregation in platelet-rich plasma (PRP). Thus, the authors concluded that PA may be a potent competitive antagonist of the P2Y 12 receptor, a pharmacological characteristic shared by the new generation of P2Y 12 receptor antagonists that are currently being investigated in clinical trials for their antiplatelet activity [31]. These results also provide evidence to suggest that purinergic receptor blockers isolated from the plants L .…”

Section: +mentioning

confidence: 88%

“…In an interesting study, Alvarado-Castillo et al [31] evaluated pomolic acid (PA), a triterpenoid isolated from L . pittieri , as a competitive antagonist of ADP-induced aggregation of human platelets.…”

Section: +mentioning

confidence: 99%

“…The authors used light transmission aggregometry to assess the ability of PA (150 nM) to inhibit PSC induced by a selective P2Y 1 receptor agonist, MRS 2365 (25 μM). They found that PA was not an antagonist of the P2Y 1 receptor [31]. It would however be interesting to use another technique like a more sensitive, high-resolution platelet sizer to assess if there is indeed any P2Y 1 purinergic effect associated with the plant isolate PA on PSC in human platelets [8].…”

Section: +mentioning

confidence: 99%

See 3 more Smart Citations

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Jagroop

2013

Purinergic Signalling

View full text Add to dashboard Cite

Adenosine diphosphate (ADP) plays a pivotal role in platelet activation. Platelet hyperactivity is associated with vascular disease and also has a key role in haemostasis and thrombosis. ADP activates platelets through three purinoceptor subtypes, the G q -coupled P2Y 1 receptor, G icoupled P2Y 12 receptor and P2X 1 ligand-gated cation channel. Platelet ADP purinergic receptors are therefore suitable targets for antiplatelet drugs. Thienopyridines such as clopidogrel and ticlopidine, as well as other ADP receptor antagonists like prasugrel, ticagrelor, cangrelor and elinogrel have demonstrated clinical benefits via the inhibition of the selective purinergic ADP receptor, P2Y 12 . However, they still have limitations in their mode of action and efficacy, like increased risk of bleeding. Thus, the ongoing pursuit to develop newer and more effective antiplatelet agents continues. There is a growing interest in the purinergic antiplatelet properties exhibited by plant extracts. This article considers the following: pomolic acid isolated from Licania pittieri, brazilin isolated from the heartwood of Caesalpinia sappan L, phylligenin isolated from the twigs of Muraltia vulpina , bark oil of Gonystylus velutinus , seed and bark extracts from Aesculus hippocastanum L . and red wine phenolics and catechins isolated from green tea. Moreover, the method used to investigate platelet purinergic receptors should be considered, since using a more sensitive, highresolution platelet sizer can sometimes detect platelet variations when the light transmission method was not able to do so. The exact mechanisms by which these plant extracts work need further investigation. They all however inhibit ADP-induced activation in human platelets. This could explain, at least in part, the protective effect of plant extracts as antiplatelet agents.

show abstract

Section: +mentioning

confidence: 86%

Section: +mentioning

confidence: 88%

Section: +mentioning

confidence: 99%

Section: +mentioning

confidence: 99%

See 2 more Smart Citations

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Jagroop

2013

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…Recent research shows that PA is not an antagonist of P2Y1 receptor, and that it behaves as a potent competitive antagonist of ADP-induced platelet aggregation, thus involving the interaction with a single binding site in platelets. PA can also be a potent competitive antagonist of P2Y12 receptor [7]. PA is an active anti-Candida albicans agent with a minimum inhibitory concentration (MIC) value of 12.5 μg/mL for C. albicans isolated from dogs, 25.0 μg/mL for C. albicans from cats, and C. albicans standard ATCC 90028 at 24 h following incubation [8].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous HPLC determination of pomolic, ursolic and euscaphic/tormentic acids in roots and rhizomes of variousPotentillaspecies

Jóźwiak¹,

Jóźwiak²,

Waksmundzka‐Hajnos³

2014

Acta Chromatographica

View full text Add to dashboard Cite

Summary.A reversed-phase high-performance liquid chromatography diode array detector (HPLC-DAD) method was developed for the separation of triterpene acids and their determination in crude extracts of Potentilla species. Symmetry octadecylsilyl silica (ODS) column with acetonitrile and water with phosphoric acid (pH = 2.5) as the mobile phase was used in the described HPLC system. The column temperature was at 20 °C, the flow rate was 0.8 mL/min. The detection wavelength was 210 nm. For quantitative purposes, the linear dependencies of analyte concentration and peak surface area were obtained with regression coefficient values 0.9983 < r 2 < 0.9995. For euscaphic acid, calibration was performed in the range of 0.07-0.525; 0.7-2.1 mg/mL, for pomolic acid in the range of 0.019-0.171; 0.209-0.665 mg/mL, for ursolic acid in the range of 0.2-1.375-3.3 mg/mL. The observed recovery of triterpene acids was from 95.3% to 103.1%. The observed values of RSD were well within the generally acceptable limit of no more than 5%. This method was successfully applied to quantify pomolic acid (PA), ursolic acid (UA) and the sum of euscaphic (EA) and tormentic acids (TA) (expressed as euscaphic acid) in roots and rhizomes of 15 various Potentilla species and 2 subspecies (i.e., P. atrosanguinea, P. recta).

show abstract

Potential clinical applications of phytopharmaceuticals for the in‐patient management of coagulopathies in COVID‐19

Mukherjee

Chattopadhyay

2022

Phytotherapy Research

View full text Add to dashboard Cite

Thrombotic complications occur in many cardiovascular pathologies and have been demonstrated in COVID‐19. The currently used antithrombotic drugs are not free of adverse reactions, and COVID‐19 patients in particular, when treated with a therapeutic dose of an anticoagulant do not receive mortality benefits. The clinical management of COVID‐19 is one of the most difficult tasks for clinicians, and the search for safe, potent, and effective antithrombotic drugs may benefit from exploring naturally bioactive molecules from plant sources. This review describes recent advances in understanding the antithrombotic potential of herbal drug prototypes and points to their future clinical use as potent antithrombotic drugs. Although natural products are perceived to be safe, their clinical and therapeutic applications are not always apparent or accepted. More in‐depth studies are necessary to demonstrate the clinical usefulness of plant‐derived, bioactive compounds. In addition, holistic approaches in systematic investigations and the identification of antithrombotic mechanisms of the herbal bioactive molecule(s) need to be conducted in pre‐clinical studies. Moreover, rigorous studies are needed to compare the potency of herbal drugs to that of competitor chemical antithrombotic drugs, and to examine their interactions with Western antithrombotic medicines. We have also proposed a road map to improve the commercialization of phytopharmaceuticals.

show abstract

Pomolic acid, triterpenoid isolated from Licania pittieri, as competitive antagonist of ADP-induced aggregation of human platelets

Cited by 14 publications

References 10 publications

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Simultaneous HPLC determination of pomolic, ursolic and euscaphic/tormentic acids in roots and rhizomes of variousPotentillaspecies

Potential clinical applications of phytopharmaceuticals for the in‐patient management of coagulopathies in COVID‐19

Contact Info

Product

Resources

About